<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:7pt Arial, sans-serif; }
 .font1 { font:8pt Arial, sans-serif; }
 .font2 { font:9pt Arial, sans-serif; }
 .font3 { font:10pt Arial, sans-serif; }
 .font4 { font:13pt Times New Roman, serif; }
 .font5 { font:19pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font5">J.P. Morgan</span></p>
<p><span class="font2" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font0" style="font-weight:bold;">07 September 2016</span></p>
<p><span class="font0" style="font-weight:bold;">Isabella Y. Zhao, CFA</span></p>
<p><span class="font0" style="font-weight:bold;">(852) 2800-8534</span></p>
<p><span class="font0" style="font-weight:bold;">¡</span><a href="mailto:sabella.zhao@jpmorgan.com"><span class="font0" style="font-weight:bold;">sabella.zhao@jpmorgan.com</span></a></p>
<p><span class="font1" style="font-weight:bold;">Pipeline: Generic drugs with high barriers-to-entry</span></p>
<table border="1">
<tr><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Therapeutic area</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Drug name</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Category</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Pre-clinical</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">Applied for clinical trial</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">Clinical trial approval</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Clinical trial</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">Applied for production</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">Production approved</span></p></td></tr>
<tr><td rowspan="2" style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">Cardiovascular</span></p>
<p><span class="font1" style="font-weight:bold;">Cardiovascular</span></p></td><td rowspan="2" style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">Limaprost Altadex tablets Clopidogrel</span></p></td><td rowspan="2" style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">Chern 3.1</span></p>
<p><span class="font1" style="font-weight:bold;">Chern 6</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td rowspan="2" style="vertical-align:top;"></td><td rowspan="2" style="vertical-align:top;"></td><td rowspan="2" style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">
<p><span class="font3">—</span></p></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Cardiovascular</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Valsarían</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Chem 6</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Cardiovascular</span></p></td><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Felodipine sustained release tablets</span></p></td><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Chem 6</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td rowspan="2" style="vertical-align:top;"></td><td rowspan="2" style="vertical-align:top;"></td><td rowspan="2" style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Cardiovascular</span></p></td><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Metoprolol succinate sustained release tablets</span></p></td><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">ANDA</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td rowspan="2" style="vertical-align:top;"></td><td rowspan="2" style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Cardiovascular</span></p></td><td rowspan="2" style="vertical-align:top;">
<p><span class="font1" style="font-weight:bold;">Fasudil</span></p>
<p><span class="font1" style="font-weight:bold;">hy drochloride injection</span></p></td><td rowspan="2" style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Chem 6</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td rowspan="2" style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
</table>
<p><span class="font1">Source: Company dale, J.P. Morgan</span></p>
<p><span class="font4">As of August, Fosun applied for an additional 37 patents in pharmaceutical manufacturing and R&amp;D, out of which 13 were U.S. patent applications and 2 PCT applications. Also, 13 licence patents were granted to Fosun, all of which were invention patents. Novel drug furuitinib (or SAF-189s) has moved into Combined</span></p>
<p><span class="font0" style="font-weight:bold;">12</span></p>
</body>
</html>